A prospective, open-label, phase 1 study of fixed-sequence pharmacokinetic drug interaction assessing effect of cannabidiol on the CYP1A2 Probe caffeine in healthy subjects
Latest Information Update: 22 Mar 2022
At a glance
- Drugs Cannabidiol (Primary) ; Caffeine
- Indications Blepharospasm; Cerebral ischaemia; Dravet syndrome; Epilepsy; Heroin-related disorders; Infantile spasms; Lennox-Gastaut syndrome; Opioid-related disorders; Parkinson's disease; Pervasive child development disorders; Rett syndrome; Schizophrenia; Sturge-Weber syndrome; Tuberous sclerosis
- Focus Adverse reactions; Pharmacokinetics
- 22 Mar 2022 New trial record